Dr. Saab on Napabucasin With Gemcitabine and Nab-Paclitaxel in Pancreatic Adenocarcinoma

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses napabucasin with gemcitabine and nab-paclitaxel in pancreatic adenocarcinoma.

In a study in pancreatic adenocarcinoma, the response rate of the combination of napabucasin with gemcitabine and nab-paclitaxel was close to 55%. This is promising, says Bekaii-Saab, as there is little response rate regularly seen in this disease.

More interestingly, the responses tended to be durable in most patients, with some approaching their second year of therapy.

<<<

View more from the 2017 World Congress on GI Cancer